No Growth For Zoetis; Analysts Expect Flat YOY Earnings

Shares of Zoetis Inc ZTS are up about 1.5 percent on Monday afternoon, in anticipation of Tuesday’s earnings call. The company is scheduled to report its first quarter financial results on Tuesday, before the market opens.

According to Estimize, the Street expects to see no earnings growth. In the first quarter of 2014, the animal health company reported EPS of $0.38 on revenue of $1.1 billion; in the last reported quarter, EPS came in at $0.40, while revenue hit $1.32 billion; for the first quarter of 2015, analysts model consensus EPS of $0.37 on revenue of $1.108 billion. The crowd has not yet weighed in.

The chart below illustrates Zoetis’ history of actual earnings versus Wall Street estimates. Although there is no clear trend, the company has beat consensus more times than it has missed it.

A second graph shows how sentiment has evolver over time.

Despite a small decline in February, the Street’s expectations have remained pretty much in the same level since the beginning of the year.

A Company That’s ‘Uniquely Positioned To Compete’

Following its 35th Annual Health Care Conference, where analysts met with big cap pharma companies’ managements, Cowen & Co published a report detailing its key findings.

Related Link: 8 Healthcare Names Cowen & Co Are Talking About

According to the note, Zoetis (rated Market Perform) is "uniquely positioned to compete; Apoquel poised for increased supply; growth promoting antibiotics small part of business; oral flea and tick opportunity not in company guidance; Q1 winter not as bad as last year."